Design of tumor-targeted nanostructured venoms for the treatment of CXCR4+ human neoplasias (VENOM4CANCER), Coordinator A. Villaverde. Intramural CIBER. 2018-25.<\/p>\n\n\n\n
Design and implementation of a novel protein-based nanobiotechnological platform for the remote delivery of tumor-targeted antitumoral drugs (NANOREMOTE). Coordinator Esther V\u00e1zquez. Intramural CIBER. 2018-25.<\/p>\n\n\n\n
Targeted nanoparticle combination for the selective killing of metastasis stem cells and metastasis associated fibroblasts in colorectal cancer (4NANOMETS). Coordinator Ram\u00f3n Mangues Bafalluy. Intramural CIBER. 2018-25.<\/p>\n\n\n\n
Design of protein nanomedicines for the targeted therapy of pancreatic cancer. PANCREATOR. Coordinador Jose Luis Corchero. Intramural CIBER. 2018-25.<\/p>\n\n\n\n
Improved colorectal cancer therapy using CXCR4-targeted functional protein nanoparticles with enhanced cytosolic release. NANOSCAPE. Coordinator Ugutz Unzueta. Intramural CIBER. 2019-25.<\/p>\n\n\n\n
Humanized nanomedicines selectively killing CXCR4+ cancer cells for Acute Myeloid Leukemia therapy. Fundaci\u00f3 La Marat\u00f3 de TV3 201941-31 (30, 31, 32). Coordinator Jordi Sierra. 399178.75 eur.<\/p>\n\n\n\n
Functionalization of DNA origami with the T22-GFP-H6 protein for the enhancement of antimetastatic properties (Nanotrojans). Intramural CIBER. 2020-25. Coordinator Ram\u00f3n Eritja.<\/p>\n\n\n\n
Targeted Reinforcement of the innate immune response Against Colorrectal Cancer (TRACC). Coordinador Eloi Parlad\u00e9. Intramural CIBER. 2021-25.<\/p>\n\n\n\n
Site-directed conjugation of multivalent protein ferrrnanomaterial for precision medicines of cancer (NANOLINK). COORDINATOR: Ugutz Unzueta. Intramural CIBER. 2021-25.<\/p>\n\n\n\n
Increase of the stability, activity and crossing of biological barriers of recombinant proteins through their vehiculization by EXtracellular vesicles and their PotentiaL biOmedical and industRial usE (EXPLORE-2). COORDINATOR: Ibane Abasolo. Intramural CIBER. 2021-25.<\/p>\n\n\n\n
Enzyme MutANts as tools in the quest for improved TheRapies for FAbry disease (MANTRA). COORDINATOR: Neus Ferrer. Intramural CIBER. 2021-25.<\/p>\n\n\n\n
Protein delivery system based on non-covalent PEGylation with telodendrimers (TELOprot). COORDINATOR: Miiam Royo. Intramural CIBER. 2021-25.<\/p>\n\n\n\n
A long-lasting anti-Covid-19 subcutaneous vaccine through a novel, industrially competitive and biologically safe nanomimetic concept (INVITA). PAND\u00c8MIES 2020. 2020PANDE00003. AGAUR. Generalitat de Catalunya. IP A. Villaverde. 349.000 eur. 13 de Mayo 2021- 12 Noviembre 2022.<\/p>\n\n\n\n
MICRO-DEPOSITOS PROTEICOS BIOMIMETICOS COMO UNA PLATAFORMA DE ADMINISTRACION SOSTENIDA DE FARMACOS EN Y A TRAVES DE LA PIEL. PID2020-116174RB-I00. 1\/09\/2021-31\/08\/2023. IP A. Villaverde. 121.000 eur.<\/p>\n\n\n\n
Membrane biophysics in lysosomal storage disorders for improved therapies (MEMPHYS). COORDINATOR: Pau Gorostiza. Intramural CIBER. 2022-25.<\/p>\n\n\n\n
In ovo vaccination of chickens against infectious bursal disease virus using ImmunoStimulatory Protein-Only Microparticles (ISPOM). IP E. Vazquez y A. Villaverde. COORDINATOR: Miquel Nofrar\u00edas. AGAUR PRODUCTE 2021 Knowledge Industry. 94.375 eur. 1\/09\/2022-31\/02\/2024.<\/p>\n\n\n\n
New protein-based nanodrugs for the development of targeted tumor-agnostic therapy. CPP2021-008946. MINISTERIO DE CIENCIA E INNOVACI\u00d3N. Nanoligent SL, Hosp Sant Pau, UAB. 2022-24. 1.357.531,86 eur. IP UAB. E. V\u00e1zquez.<\/p>\n\n\n\n
Time-sustained therapy of metastatic cancer from secretable nanoparticles. PDC2022-133858-I00. MINISTERIO DE CIENCIA E INNOVACI\u00d3N. 2022-2024. 146.050 \u20ac. IP. E. V\u00e1zquez.<\/p>\n\n\n\n
Grupo de Investigaci\u00f3n Consolidado de Catalunya en Biof\u00e1rmacos Innovadores (Grup de Recerca Consolidat de Catalunya en Bio-f\u00e0rmacs innovadors). 2021 SGR00092. 2022-2024. A. Villaverde. 40.000 eur.<\/p>\n\n\n\n
Estrategias innovadoras para terapia contra c\u00e9lulas madre tumorales: activando receptores de dopamina con nanopart\u00edculas proteicas (PI20\/00770). Coordinador: JL Corchero. Instituto de Salud Carlos III (Proyectos de Investigaci\u00f3n en Salud, convocatoria 2020 de la Acci\u00f3n Estrat\u00e9gica en Salud). 76.230 \u20ac.<\/p>\n\n\n\n
Advanced Extracellular Vesicles for Enzyme Replacement Therapy (ADVERT). Coordinador: Jos\u00e9 Luis Corchero. Instituto de Salud Carlos III-CIBER-BBN (Proyectos de Valorizaci\u00f3n CIBER-BBN) 2021-2022. 20.000 \u20ac.<\/p>\n\n\n\n
ARTIFICIAL SECRETION GRANULES FOR REMOTE DELIVERY OF ANTITUMORAL DRUGS. Ministerio de Ciencia e Innovaci\u00f3n (PID2019-105416RB-I00) UAB. 2020-\u00a02023.\u00a0Esther V\u00e1zquez. 145.200<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
Increase of the stability, activity and crossing of biological barriers of recombinant proteins through their vehiculization by EXtracellular vesicles and their PotentiaL biOmedical and industRial usE (EXPLORE-3). Coordinador: Ibane Abasolo. Intramural CIBER. 2023-2024<\/p>\n\n\n\n
Tumor extracellular vesicles as nanobeacons for personalized diagnosis of triple negative breast cancer patients (Nanobeacon). Coordinador: Joaquim Seras-Franzoso. Intramural CIBER. 2023-2024<\/p>\n\n\n\n
Improved drug delivery systems for enzyme replacement therapies in Fabry disease. Effect of targeting, and protein corona in the efficacy of nanosystems (PEGLyso-2). Coordinador: Ibane Abasolo. Intramural CIBER 2023-2024<\/p>\n\n\n\n
Local and Systemic Enzyme Replacement Therapies for Pycnodysostosis (PYCNO-2). Coordinador Ibane Abasolo. Intramural CIBER 2023-2024<\/p>\n\n\n\n
Redes reguladoras de quorum sensing en Stenotrophomonas maltophilia como dianas para alternativas terap\u00e9uticas a los antibi\u00f3ticos actuales (StenoQS). PID2019-111364RB-I00. IP Xavier Daura y Daniel Yero. 157.300 eur. 2020-2024.<\/p>\n\n\n\n
Enzyme propelled nanobots as efficient nanotech platform for bladder cancer therapy. \u201cla Caixa\u201d Banking Foundation Health Research 2021 Call. Ref.: HR21-00208; 01\/10\/2021-30\/09\/2024. IP: E. Juli\u00e1n. 997.946,50 \u20ac.<\/p>\n\n\n\n
Nueva generaci\u00f3n de agentes inmunoterap\u00e9uticos basados en micobacterias no tuberculosas modificadas (NextNTMdrugs). Ministerio de Ciencia, Innovaci\u00f3n y Universidades. PID2021-122331OB-I00; 01\/09\/2022-31\/08\/2025. IP: E. Juli\u00e1n. 242.000 \u20ac.<\/p>\n\n\n\n
NEW FORMULATION OF RECOMBINANT ANTITUMOR VACCINES BASED ON SECRETORY GRANULES FOR SUSTAINED RELEASE (SECRETVAC). MINISTERIO DE CIENCIA E INNOVACI\u00d3N (PID2022-136845OB-I00). UAB. 2023- 2026. IP \u00a0Antonio Villaverde, Esther V\u00e1zquez. 193.750\u20ac<\/p>\n\n\n\n
PROTEIN-BASED NANOPARTICLES FOR NOSE-TO-BRAIN DELIVERY TO TREAT OBESITY (NANOBESITY) AGAUR (Generalitat de Catalunya) (2023 PROD 00094).\u00a0Universidad Internacional de Catalunya (UIC), Universidad Aut\u00f2noma de Barcelona (UAB). 2024-2025. IPs E. V\u00e1zquez, A. Villaverde (Coordinator R. Rodr\u00edguez). \u00a0150.000\u20ac.<\/p>\n\n\n\n
Time-sustained therapy of metastatic cancer from secretable nanoparticles. MINISTERIO DE CIENCIA E INNOVACI\u00d3N (PDC2022-133858-I00). UAB. 2022-2024. IP E. V\u00e1zquez. 146.050 \u20ac<\/p>\n\n\n\n
New protein-based nanodrugs for the development of targeted tumor-agnostic therapy. \u00a0MINISTERIO DE CIENCIA E INNOVACI\u00d3N\u00a0(CPP2021-008946). Nanoligent SL, Universidad Aut\u00f3noma de Barcelona y Instituto de Investigaci\u00f3n del Hospital de La Santa Creu y de San Pau. 2022-2024. IP\u00a0E. V\u00e1zquez (coordinated by Nanoligent).\u00a01.689.076,01\u00a0\u20ac<\/p>\n\n\n\n
In ovo vaccination of chickens against infectious bursal disease virus using ImmunoStimulatory Protein-Only Microparticles (ISPOM). AGAUR (PRODUCTE) (2021 PROD 00196). \u00a0IRTA, UAB. \u00a02022-2024. IP. E. Vazquez.\u00a094.375 \u20ac<\/p>\n\n\n\n
BASED NANOPARTICLES FOR NOSE-TO-BRAIN DELIVERY TO TREAT OBESITY (NANOBESITY) AGAUR (Generalitat de Catalunya) (2023 PROD 00094).\u00a0Universidad Internacional de Catalunya (UIC), Universidad Aut\u00f2noma de Barcelona (UAB). 2024-2025. IPs E. V\u00e1zquez, A. Villaverde (Coordinator R. Rodr\u00edguez). \u00a0150.000\u20ac.<\/p>\n\n\n\n
Multifunctional all-protein-based nanoparticles for nose-to-brain delivery. Prestaci\u00f3n de servicios en el contexto de una colaboraci\u00f3n cient\u00edfica. Universitat Internacional de Catalunya. 2022-2023 IPs: Esther V\u00e1zquez, Antonio Villaverde. 3.000 \u20ac<\/p>\n\n\n\n
Convenio de colaboraci\u00f3n entre la Universidad Aut\u00f3noma de Barcelona y la sociedad Nanoligent S.L. IPs: Esther V\u00e1zquez, Antonio Villaverde. 2000\u20ac <\/p>\n\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Design of tumor-targeted nanostructured venoms for the treatment of CXCR4+ human neoplasias (VENOM4CANCER), Coordinator A. Villaverde. Intramural CIBER. 2018-25. Design and implementation of a novel protein-based nanobiotechnological platform for the remote delivery of tumor-targeted antitumoral drugs (NANOREMOTE). Coordinator Esther V\u00e1zquez. Intramural CIBER. 2018-25. Targeted nanoparticle combination for the selective killing of metastasis stem cells and […]<\/p>\n","protected":false},"author":1555,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-42","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/webs.uab.cat\/innovative-biodrugs\/wp-json\/wp\/v2\/pages\/42","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webs.uab.cat\/innovative-biodrugs\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/webs.uab.cat\/innovative-biodrugs\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/webs.uab.cat\/innovative-biodrugs\/wp-json\/wp\/v2\/users\/1555"}],"replies":[{"embeddable":true,"href":"https:\/\/webs.uab.cat\/innovative-biodrugs\/wp-json\/wp\/v2\/comments?post=42"}],"version-history":[{"count":11,"href":"https:\/\/webs.uab.cat\/innovative-biodrugs\/wp-json\/wp\/v2\/pages\/42\/revisions"}],"predecessor-version":[{"id":92,"href":"https:\/\/webs.uab.cat\/innovative-biodrugs\/wp-json\/wp\/v2\/pages\/42\/revisions\/92"}],"wp:attachment":[{"href":"https:\/\/webs.uab.cat\/innovative-biodrugs\/wp-json\/wp\/v2\/media?parent=42"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}